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INTRODUCTION
Chronic  kidney  disease  (CKD)  has  been  considered  an 
uncommon condition requiring specialist management. The 
traditional view of CKD has been of patients with end-stage 
renal disease (ESRD) requiring dialysis or a kidney transplant 
as  forms  of  renal  replacement  therapy  (RRT).  However 
the  prevalence  of  CKD  is  much  higher  than  previously 
appreciated and this has provided a stimulus to the integration 
of  primary  and  secondary  care  to  optimise  the  health  of 
persons with CKD. In particular up to 40% of ESRD patients 
had been referred to specialists shortly before they needed 
dialysis. Such late referral often results in increased morbidity 
and mortality for patients and poor acceptance and planning 
for RRT1,2. 
In 2002, in response to growing evidence confirming the 
benefit of early versus late renal specialist input, the UK Renal 
Association proposed that all patients with a serum creatinine 
level  >150  µmol/L  should  be  referred  to  a  nephrologist3. 
However,  it  soon  became  apparent  that  the  community 
prevalence of CKD had been grossly underestimated and strict 
adherence to this guideline would simply have overwhelmed 
existing renal services4. Although the majority of persons with 
CKD will never progress to ESRD, they do have an increased 
rate of cardiovascular events and risk of premature death5.
Subsequently, in January 2005, the second part of the National 
Service Framework for Renal Services set standards relating 
to the prevention, early detection and minimisation of CKD 
progression6. The widespread adoption of a formula based 
estimation of glomerular filtration rate (eGFR), to be reported 
by all biochemical laboratories, was recommended to help 
achieve these goals. The traditional means of assessing renal 
function using serum creatinine is limited by the variability 
of this parameter with muscle bulk and age. The degree of 
renal dysfunction, especially in women and older people, can 
be underestimated using serum creatinine levels alone and is 
a major factor in delayed recognition and referral of CKD 
patients. An eGFR provides a more accurate measurement of 
kidney impairment. An internationally agreed categorisation 
of CKD based on a four-variable eGFR equation incorporating 
age, gender, race and serum creatinine, is now widely utilised 
(Table I). 
UK  Guidelines  for  the  management  of  CKD,  developed 
by the Royal College of Physicians, the Royal College of 
General Practitioners and the Renal Association were also 
published in 20057. Recommendations followed suggesting 
that the markers for quality of care of CKD be incorporated 
into the Quality and Outcomes Framework (QOF) to enable 
full implementation of the guidelines across the National 
Health Service.
Consequently the updated General Practice QOF specified 
four indicators (accounting for 27 points) in relation to CKD. 
These depend on the generation of a register of patients with 
CKD (eGFR <60mls / min / 1.73m2), measurement of blood 
pressure, treatment of blood pressure to target, and greater use 
(if appropriate) of angiotensin converting enzyme inhibitor 
or angiotensin receptor blocker medication in patients with 
CKD (Table II)8. 
Ta b l e  I
International classification of chronic kidney disease
Stage eGFR mls/
min/1.73m2 Description
1 90+ Normal kidney 
function
With urinary 
or structural 
abnormalities
2 60-89 Mildly reduced 
kidney function
With urinary 
or structural 
abnormalities
3* 30-59
Moderately 
reduced kidney 
function
With or 
without urinary 
abnormalities
4* 15-29 Severely reduced 
kidney function
With or 
without urinary 
abnormalities
5* <15 Established renal 
failure 
Very severe 
or dialysis- 
dependent 
kidney failure
* Stages 3-5 are the stages of CKD currently recognized within 
the General Practice Quality and Outcomes Framework and thus 
identified with eGFR reporting. © The Ulster Medical Society, 2007.
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In Northern Ireland in 2006 the Clinical Resource Efficiency 
Support Team (CREST) published specific guidelines on CKD 
management9, the General Practice QOF targets for CKD 
were introduced, and all laboratories began to routinely report 
eGFR with any creatinine measurement. These developments 
were coupled to local educational initiatives to explain and 
disseminate best practice for the care of persons with CKD. 
What conclusions can be drawn from this first year of eGFR 
reporting in Northern Ireland?
CKD IS COMMON
Patients with an eGFR <60ml/min/1.73m2 have CKD stage 
3, 4 or 5 and are the focus of guidelines and the new QOF 
indicators. The epidemiological evidence has confirmed that 
CKD is common in Northern Ireland with approximately 5% 
of the adult population having CKD stages 3, 4 or 54. The 
majority of these patients are elderly and although they have 
minor elevation of serum creatinine they are categorized as 
having stage 3 CKD based on eGFR. Some clinicians are 
concerned that use of eGFR generates a ‘disease’ that may 
merely be age related kidney function decline. However the 
data supporting a high risk of cardiovascular events in CKD 
stage 3 patients is robust and since the growth in ESRD 
incidence  is  largely  confined  to  the  elderly  we  consider 
the benefits of this staging system outweighs this putative 
drawback.  
CKD IS INCREASINGLY RECOGNISED
The identification of patients with CKD has increased following 
routine  eGFR  reporting  coupled  with  implementation  of 
CKD QOF criteria. Electronic registers of persons with an 
eGFR < 60 ml/min/1.73m2 now exist in general practice and 
will heighten awareness of opportunities for reduction of 
cardiovascular risk and reduce the likelihood of prescribing 
problems in persons with renal impairment.
THE MAJORITY OF CKD IS 
MANAGED IN PRIMARY CARE
For CKD patients, the guidelines recommend 
targeting classical cardiovascular risk factors, 
including meticulous control of blood pressure 
and lipids, smoking cessation, lifestyle advice 
and, in diabetic patients, optimisation of blood 
sugar control. Since many of these patients’ 
main risk is cardiovascular in nature the most 
relevant and cost-effective place for this to 
happen is primary care, as suggested by the 
guidelines  for  CKD7. The  local  guidelines 
provide specific advice on those who would 
benefit from specialist input9, and a summary 
version has been distributed to GPs (fig 1). 
AN IMPORTANT MINORITY 
PROGRESS TO END-STAGE RENAL 
DISEASE
Unfortunately  some  people  with  CKD 
stages 3 and 4 will progress to ESRD (stage 
5  CKD)  and  require  dialysis.10  Diabetes, 
hypertension and proteinuria are all predictors 
for progressive renal failure. The number of 
people with ESRD requiring RRT continues 
to rise worldwide placing an increasing strain 
Ta b l e  II.
Quality and Outcomes Framework indicators for Chronic 
Kidney Disease
Indicator Points
Records
CKD 1
The practice can produce a 
register of patients aged 18 years 
and over with CKD stages 3-5
6
Initial 
management
CKD 2
The percentage of patients on the 
CKD register whose notes have 
a record of blood pressure in the 
previous 15 months 
6
On-going 
management
CKD 3 
The percentage of patients on the 
CKD register in whom the last 
blood pressure reading, measured 
in the previous 15 months, is 
140/85 or less 
11
CKD 4 
The percentage of patients on the 
CKD register with hypertension 
who are treated with an 
angiotensin converting enzyme 
inhibitor (ACE-I) or angiotensin 
receptor blocker (ARB) (unless 
a contraindication or side effects 
are recorded) 
4
Figure 1.  The summary of chronic kidney disease management guidelines 
recommended by CREST© The Ulster Medical Society, 2007.
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on limited healthcare resources. In Northern Ireland, at the 
start of 2007, over 750 patients were receiving regular dialysis 
therapy with the absolute number of dialysis patients predicted 
to rise to over 1000 by the end of 2010. While the provision 
of RRT in Northern Ireland compares very favourably with 
the rest of the UK, (the dialysis take-on rate here is the higher 
than all other UK regions)11, the UK has the lowest dialysis 
provision per million population in the developed world. It 
is projected that prevalent dialysis patient numbers will not 
reach steady state for at least a further 20 to 25 years11. 
RRT is expensive with an estimation that in the near future 
it will account for 2% of the total NHS budget.7 Despite the 
commendable dialysis take-on rate in Northern Ireland there 
has been evidence of both under- and late-referral4,12. CKD 
must therefore remain a high profile public health issue. The 
identification and early referral of the subgroup of patients that 
would benefit from specialist renal input will reduce the costs 
incurred by late referral2. However before realizing this there 
will need to be an increase in nephrology outpatient services 
to support primary care colleagues in this endeavour.
There are testing times ahead for primary and secondary 
care health professionals managing persons with CKD. The 
introduction of eGFR reporting has provided a useful tool to 
recognise the burden of CKD in the community and to track 
the progression of kidney disease in an individual over time.   
The authors have no conflict of interest. 
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